+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a preservative-free formulation of Bimatoprost ophthalmic solution 0.01% YSBP compared to Lumigan49 bimatoprost ophthalmic solution 0.01% in adults with primary open-angle glaucoma POAG or ocular hypertension OH. The purpose is to establish whether YSBP is not less effective than Lumigan49 in lowering eye pressure in these patients. Participants will be randomly assigned to receive either YSBP or Lumigan49 eye drops. Both treatments contain bimatoprost 0.01%, and the study is designed as a double-blind, active-controlled, parallel-group trial. The treatment period lasts 12 weeks, during which participants will use the assigned eye drops as directed. During the study, participants will undergo regular eye pressure measurements, including the primary outcome of intra-ocular pressure at Week 12. Visual acuity and safety assessments will also be performed. Women of childbearing potential must use effective contraception. The study includes screening, a washout period for prior eye medications, treatment visits, and safety monitoring through the completion date in late 2027.

Age: 18Years +All GendersPhase 3
22 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of DFL24498 eye drops compared to a placebo vehicle in people aged 10 to 65 with atopic keratoconjunctivitis AKC, a condition affecting the eyes. This phase 3 study is randomized, double-masked, and conducted at multiple centers. It includes two groups adults and children, with adults equally assigned to receive DFL24498 or placebo, while children are more likely to receive DFL24498. The study has three parts a washout period lasting about one week before treatment starts, a 12-week treatment period where participants receive either DFL24498 or placebo eye drops in both eyes, and a follow-up period from weeks 13 to 16. Rescue medication with dexamethasone sodium phosphate may be given if needed during the study. Participants are monitored throughout these stages. During the study, participants will have their eye symptoms such as itching, redness, and corneal damage measured at various times including baseline, week 4, week 6, week 8, week 12, and week 16. Quality of life and global impression of change assessments are done in adults. Safety is closely monitored, including any side effects or adverse events, with vision and eye pressure also evaluated. The main outcome is the change in eye itching at week 6 compared to the start of treatment.

Age: 10Years - 65YearsAll GendersPhase 3
19 locations
E

Actively Recruiting

Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.

Age: 18Years +All GendersPhase 2
24 locations
A

Actively Recruiting

Researchers are evaluating the bioequivalence of two eye drop treatments, Bimatoprost 0.01% ophthalmic solution by Amneal EU and LUMIGAN4 bimatoprost ophthalmic solution 0.01% by Allergan, in adults with chronic open-angle glaucoma or ocular hypertension affecting both eyes. This randomized, double-blind, parallel-group study aims to compare these treatments by measuring their effects on intraocular pressure IOP as the primary clinical endpoint. Participants will be randomly assigned to receive either the test or reference bimatoprost eye drops, instilling one drop in both eyes every evening around 1000 pm for 42 days. The study includes multiple doses over this period, with evaluations occurring at baseline, two weeks, and six weeks. The test and reference products are both ophthalmic solutions containing the same concentration of bimatoprost. Throughout the study, participants will have clinical assessments to monitor safety and efficacy, including IOP measurements at specific times 0000, 0400, and 0800 hours on days 14 and 42. Safety monitoring for adverse events will continue during the six-week treatment period. The main outcome is the mean difference in IOP between the treatment groups, helping to determine if the test product is equivalent to the reference product in controlling eye pressure.

Age: 18Years +All GendersPhase 3
9 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations